EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 33 / No 10 (Octobre 2017) Med Sci (Paris), 33 10 (2017) 822-824 References
Free Access
Issue
Med Sci (Paris)
Volume 33, Number 10, Octobre 2017
Page(s) 822 - 824
Section Nouvelles
DOI https://doi.org/10.1051/medsci/20173310004
Published online 10 October 2017
  1. Pagonabarraga J, Kulisevsky J, Strafella AP, et al. Apathy in parkinson’s disease: Clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol 2015 ; 14 : 518–531. [CrossRef] [PubMed] [Google Scholar]
  2. Chaudhuri KR, Odin P. The challenge of non-motor symptoms in parkinson’s disease. Prog Brain Res 2010 ; 184 : 325–341. [CrossRef] [PubMed] [Google Scholar]
  3. Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex 2006 ; 16 : 916–928. [CrossRef] [PubMed] [Google Scholar]
  4. Schmidt L, d’Arc BF, Lafargue G, et al. Disconnecting force from money: Effects of basal ganglia damage on incentive motivation. Brain 2008; 131 : 1303–1310. [CrossRef] [PubMed] [Google Scholar]
  5. Drui G, Carnicella S, Carcenac C, et al. Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in parkinson’s disease. Mol Psychiatry 2014 ; 19 : 358–367. [CrossRef] [PubMed] [Google Scholar]
  6. Favier M, Duran T, Carcenac C, et al. Pramipexole reverses parkinson’s disease-related motivational deficits in rats. Mov Disord 2014 ; 29 : 912–920. [CrossRef] [PubMed] [Google Scholar]
  7. Carnicella S, Drui G, Boulet S, et al. Implication of dopamine d3 receptor activation in the reversion of parkinson’s disease-related motivational deficits. Transl Psychiatry 2014 ; 4 : e401. [CrossRef] [PubMed] [Google Scholar]
  8. Magnard R, Vachez Y, Carcenac C, et al. What can rodent models tell us about apathy and associated neuropsychiatric symptoms in parkinson’s disease?. Transl Psychiatry 2016 ; 6 : e753. [CrossRef] [PubMed] [Google Scholar]
  9. Rangel-Barajas C, Coronel I, Floran B. Dopamine receptors and neurodegeneration. Aging Dis 2015 ; 6 : 349–368. [Google Scholar]
  10. Hurley MJ, Jenner P. What has been learnt from study of dopamine receptors in parkinson’s disease?. Pharmacol Ther 2006 ; 111 : 715–728. [CrossRef] [PubMed] [Google Scholar]
  11. Beaulieu JM, Espinoza S, Gainetdinov RR. Dopamine receptors: iuphar review 13. Br J Pharmacol 2015 ; 172 : 1–23. [CrossRef] [PubMed] [Google Scholar]
  12. Thibault D, Kortleven C, Fasano C, et al. Découvertes récentes sur la fonction et la plasticité des voies dopaminergiques du cerveau. Med Sci (Paris) 2010 ; 26 : 165–170. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  13. Favier M, Carcenac C, Drui G, et al. Implication of dorsostriatal d3 receptors in motivational processes: a potential target for neuropsychiatric symptoms in parkinson’s disease. Sci Rep 2017 ; 7 : 41589. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.